← Back to Search

Targeted Therapy

Matched Targeted Therapy for High-Risk Leukemia

Q: To what extent is this medical experiment being conducted across various sites?

<p>This clinical trial has 15 operating sites, including Children's Hospital of Philadelphia in Philadelphia, Columbia University Medical Center in <a href="https://www.withpower.com/clinical-trials/new-york">New york</a> and Roswell Park Comprehensive <a href="https://www.withpower.com/clinical-trials/cancer">Cancer</a> Center in Buffalo. Furthermore there are 12 additional medical centers offering this medication to patients.</p>

Q: Are there still opportunities to join this research endeavor?

<p>As reported on clinicaltrials.gov, this trial is currently not recruiting patients despite its launch in February 2016 and last update November 2022. However, there are an abundance of other medical studies that are actively accepting participants; 2344 to be exact.</p>

N/A

Waitlist Available

Led By Yana Pikman, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Cohort 1: Relapsed/refractory leukemia - Acute lymphoblastic leukemia (ALL), first or greater relapse - Acute myeloid leukemia (AML), first or greater relapse - Leukemia refractory to induction chemotherapy - Other recurrent leukemia - Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy

Cohort 2: New diagnosis - Acute myeloid leukemia (AML), new diagnosis - New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (<40 chromosomes) ALL - Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage - Secondary leukemia - Myelodysplastic syndrome (MDS) not eligible for stem cell transplant

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is seeking to find new ways to treat leukemia in children and young adults who have either not responded to treatment, had their cancer come back after treatment, or have a high risk of the cancer coming back.

Who is the study for?

This trial is for children and young adults up to 30 years old with high-risk leukemias or myelodysplastic syndrome (MDS), including those who have relapsed, are refractory to treatment, or newly diagnosed with certain types. Participants must have a confirmed diagnosis and sufficient leukemia samples available for profiling.Check my eligibility

What is being tested?

The study focuses on leukemia profiling to identify specific cancer therapies tailored to the patient's unique condition. An expert panel reviews the results, which may lead to recommendations for matched targeted therapy (MTT) that will be shared with the participant's primary oncologist.See study design

What are the potential side effects?

Since this trial involves testing and personalized therapy recommendations rather than direct administration of drugs, side effects would depend on the individual treatments chosen based on profiling results.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My leukemia has returned or didn't respond to initial treatment.

Select...

I have a new diagnosis of a rare or specific type of leukemia and am not eligible for a stem cell transplant.

Select...

My leukemia was confirmed through lab tests.

Select...

I am 30 years old or younger.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of Patients With Actionable Alterations

Secondary outcome measures

Analysis of Primary Leukemia Sensitivity Testing and Establishment of Xenograft Models

Parent's Feelings and Understanding of Genomic Testing

Rate of Results Reporting

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Relapsed/Refractory LeukemiaExperimental Treatment1 Intervention

Cohort 1: Relapsed/Refractory Leukemia Acute lymphoblastic leukemia (ALL), first or greater relapse Acute myeloid leukemia (AML), first or greater relapse Leukemia refractory to induction chemotherapy Other recurrent leukemia Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy After the screening procedures confirms patient eligibility: Leukemia Profiling will be performed Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.

Group II: New DiagnosisExperimental Treatment1 Intervention

Cohort 2: New Diagnosis Acute myeloid leukemia (AML), new diagnosis (excluding acute promyelocytic leukemia (APL)) New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (<40 chromosomes) ALL Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage Secondary leukemia Myelodysplastic syndrome (MDS) not eligible for stem cell transplant After the screening procedures confirms eligibility: Leukemia Profiling will be performed Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation.

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,078 Previous Clinical Trials

340,534 Total Patients Enrolled

77 Trials studying Leukemia

10,082 Patients Enrolled for Leukemia

Yana Pikman, MDPrincipal Investigator - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

1 Previous Clinical Trials

300 Total Patients Enrolled

1 Trials studying Leukemia

300 Patients Enrolled for Leukemia

Media Library

Matched Targeted Therapy (Targeted Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02670525 — N/A

$Leukemia Research Study Groups: Relapsed/Refractory Leukemia, New Diagnosis$

Leukemia Clinical Trial 2023: Matched Targeted Therapy Highlights & Side Effects. Trial Name: NCT02670525 — N/A

Matched Targeted Therapy (Targeted Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02670525 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is this medical experiment being conducted across various sites?

"This clinical trial has 15 operating sites, including Children's Hospital of Philadelphia in Philadelphia, Columbia University Medical Center in New york and Roswell Park Comprehensive Cancer Center in Buffalo. Furthermore there are 12 additional medical centers offering this medication to patients."

Answered by AI

Are there still opportunities to join this research endeavor?

"As reported on clinicaltrials.gov, this trial is currently not recruiting patients despite its launch in February 2016 and last update November 2022. However, there are an abundance of other medical studies that are actively accepting participants; 2344 to be exact."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Yana Pikman, MD 2016. "Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02670525.

All > Acute Myeloid Leukemia > Paid Studies Wisconsin